Adjuvant Goserelin for Early-Stage Breast Cancer

Goserelin was effective in premenopausal women during long-term follow-up.

An overview of randomized trials showed that luteinizing-hormone–releasing hormone (LHRH) agonists were effective in treating premenopausal women with hormone receptor–positive breast cancer (Lancet 2007; 369:1711). The overview included results from the Zoladex in Premenopausal Patients (ZIPP) study, a randomized, 2×2 factorial trial, which showed that the addition of the LHRH agonist goserelin (Zoladex) to standard adjuvant therapy was more effective than standard therapy alone during median follow-up of 5.5 years (Eur J Cancer 2006; 42:895).

Now, investigators have assessed outcomes in 2706 ZIPP study patients during median follow-up of 12 years. ZIPP study patients were assigned to 2 years of goserelin (3.6 mg by injection every 4 weeks)…

Reviewing Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)